Mr. Gunn joined Corcept in July 2024 and was named President of Endocrinology in October 2026.  He previously held the role of Vice President of Sales and Commercial Learning for the company’s Oncology division, overseeing the field sales and training teams responsible for the launch of the company’s first oncologic medicine. Mr. Gunn has more than 25 years of experience in the biotechnology and pharmaceutical industries and has managed the successful launch of products spanning multiple therapeutic areas. Prior to Corcept, Mr. Gunn spent nearly 18 years with Gilead Sciences, where he led commercial sales teams in a diversity of categories, including cardiovascular disease, respiratory disease, oncology and virology. He previously held marketing and sales roles of increasing seniority at Merck and Sepracor.  Mr. Gunn holds a Bachelor of Science degree in business administration from the University of Arkansas.